Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology Convergence 2026
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
